Ganaplacide-Lumefantrine

Novartis

Product vision
  • Uncomplicated malaria treatment and resistance management
  • Potential for prophylaxis
MoA
  • Recent data suggest effect on parasite internal protein secretory pathway. Target not yet fully determined. Decreased susceptibility to ganaplacide is associated with mutations in three P. falciparum genes, CARL (cyclic amine resistance locus), UDP-galactose and Acetyl-CoA transporters
Key features

Ganaplacide

  • Novel mechanism of action – activity against parasites that are resistant to current drugs

  • Rapid killing of parasites (parasite clearance time <48 hours)
  • Effective against P. falciparum and P. vivax species
  • Transmission-blocking activity in a Standard Membrane Feeding Assay
  • Potential for causal prophylaxis by blocking early liver stage of parasite

Lumefantrine

  • New lumefantrine formulation with improved bioavailability allowing once daily administration 
Status
  • Phase IIb combination studies ongoing
  • Phase IIb combination study ongoing (recruitment completed)
  • Phase IIb study in paediatric population (KALUMI) ongoing
Next milestone
  • Completion of Phase IIb studies

Previously
  • Previous names: KAF156, GNF156. Novartis in discovery partnership with MMV, Wellcome Trust, and the Swiss Tropical and Public Health Institute
MMV Project Director
  • Dr Gonzalo Acuña